MedTrace Logo

Optical Coherence Tomography to Evaluate Ticagrelor and Clopidogrel

NCT02140801 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 352

Last updated 2018-03-21

No results posted yet for this study

Summary

A number of 352 patients scheduled for elective percutaneous coronary intervention (PCI) with a native coronary stenosis suitable for DES implantation and OCT imaging are openly randomized 1:1 to either BRILINTA™ (ticagrelor) or Plavix® (clopidogrel bisulfate).

Conditions

Interventions

DRUG

Ticagrelor

Plain, round, yellow, filmcoated tablet, 90 mg

DRUG

Clopidogrel

Orange brown capsule, containing one 75 mg clopidogrel tablet (cut into 2 halves)

Sponsors & Collaborators

  • Nanjing First Hospital, Nanjing Medical University

    lead OTHER

Principal Investigators

  • Shaoliang Chen, MD · The First Affiliated Hospital with Nanjing Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-01
Primary Completion
2017-03-08
Completion
2017-03-08
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02140801 on ClinicalTrials.gov